Clinical trials: Adult Attention Deficit Hyperactivity Disorder
- Condition Adult Attention Deficit Hyperactivity Disorder
- Funder type Industry (pharma, biotech, devices)
ADHD
A Novel Device for the Management of ADHD
This is a 2-months study, where eligible ADHD adult participants will be provided with personalized VIZO glasses.
- Trial name
- NCT05777785
- Testing
- VIZO Glasses
- Where
- Israel
- Volunteers
- 108 people
- Sponsor
- VIZO Specs Ltd
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
The study is designed to evaluate the efficacy and safety of each dose of SHP465 (12.5 and 37.5 mg) given to participants daily in the morning compared to placebo in the treatment of adults aged 18 to 55 years diagnosed with ADHD.
- Trial name
- NCT02604407
- Testing
- SHP465 12.5mg capsules (one capsule daily), SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
- Where
- 45 sites in United States
- Volunteers
- 275 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
This was a Phase 2b, randomized, double-blind, multicenter, 2-period, 2-treatment, crossover study to evaluate safety and efficacy of CTN SR compared with placebo in adults with ADHD.
- Trial name
- NCT02547428
- Testing
- CTN SR
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention-Deficit/Hyperactivity Disorder
Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder
The primary objective of this study is to evaluate the maintenance of efficacy, as measured by Adult ADHD Rating Scale with Prompts (Adult ADHD-RS with prompts) and Clinical Global Impression - Severity (CGI-S) scores, through a…
- Trial name
- NCT00877487
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 55 sites in United States
- Volunteers
- 123 people
- Sponsor
- Shire
Attention-Deficit Hyperactivity Disorder
An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate the efficacy of JNS001 titrated to daily doses of 18 to 72 mg in adults with attention-deficit hyperactivity disorder (ADHD) relative to placebo.
- Trial name
- NCT01323192
- Testing
- JNS001
- Where
- 30 sites in Japan
- Volunteers
- 284 people
- Sponsor
- Janssen Pharmaceutical K.K.
Attention Deficit/ Hyperactivity Disorder
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy of 2 fixed dosages of Prolonged Release (PR) OROS methylphenidate (54 and 72 mg/day) compared with placebo in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00714688
- Testing
- prolonged release (PR) OROS methylphenidate 54 mg, prolonged release (PR) OROS methylphenidate 72 mg
- Where
- 42 sites in Belgium, Denmark and 9 more
- Volunteers
- 279 people
- Sponsor
- Janssen-Cilag International NV
Attention Deficit Disorder With Hyperactivity
CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults
The purpose of this pilot study is to evaluate the safety, tolerability and potential effectiveness of CONCERTA® (methylphenidate hydrochloride extended-release tablets), a central nervous system (CNS) stimulant for the…
- Trial name
- NCT00246207
- Testing
- CONCERTA (OROS methylphenidate hydrochloride)
- Volunteers
- 32 people
- Sponsor
- Janssen-Ortho Inc., Canada
Cerebrovascular Accident, Transient Ischemic Attack
Safety Study of Atomoxetine and Cerebrovascular Outcomes
Using a proprietary insurance health claims database, Eli Lilly and Company has contracted with an external party to conduct a retrospective cohort study of health claims for the time period from 1 January 2003 through 31…
- Conditions
- Cerebrovascular Accident, Transient Ischemic Attack, ADHD
- Trial name
- NCT00634439
- Testing
- atomoxetine, Stimulants, No intervention (general population)
- Where
- United States
- Volunteers
- 72,000 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT03605849
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
Assessing Mobile Apps for Adult ADHD
The purpose of this clinical trial is to evaluate the effects of mobile app digital therapies on cognitive function and symptoms in adults diagnosed with ADHD.
- Trial name
- NCT06256003
- Testing
- UC-A, UC-N
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Think Now Incorporated
Attention Deficit Hyperactivity Disorder
Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy, safety and to assess the impact of the treatment on quality of life of long-acting methylphenidate in adult participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00783835
- Testing
- Long-Acting Methylphenidate
- Where
- 5 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Attention-Deficit/Hyperactivity Disorder (ADHD)
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
The purpose of this study is to investigate the safety and efficacy of an investigational treatment for Attention Deficit Hyperactivity Disorder (ADHD) when compared to placebo.
- Trial name
- NCT00475735
- Testing
- MK0249, Concerta (methylphenidate)
- Volunteers
- 72 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit Disorder With Hyperactivity
A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.
The purpose of this study is to evaluate the effectiveness and safety of three doses of prolonged-release methylphenidate (a central nervous system (CNS) stimulant) in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00246220
- Testing
- methylphenidate hydrochloride
- Volunteers
- 402 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Adult Attention Deficit Hyperactivity Disorder
Open-label Safety Study in Adults With ADHD
To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD)
- Trial name
- NCT02160262
- Testing
- Dasotraline
- Where
- 65 sites in United States
- Volunteers
- 724 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Disorder With Hyperactivity
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Trial 42603ATT3004 is an open-label extension study to clinical trial 42603ATT3002 (NCT00246220). In trial 42603ATT3002 the efficacy and safety of OROS methylphenidate was assessed in adult subjects with Attention Deficit…
- Trial name
- NCT00307684
- Testing
- double blind PR OROS methylphenidate, open label PR OROS methylphenidate
- Where
- 21 sites in France, Germany and 5 more
- Volunteers
- 155 people
- Sponsor
- Janssen-Cilag International NV
Attention Deficit Hyperactivity Disorder (ADHD)
A Study on the Use of Healthcare Resources and Costs of Attention Deficit Hyperactivity Disorder (ADHD) in Adults in England
The main aim of the study is to learn about the demographic and clinical characteristics, healthcare resources utilization (HCRU) and costs associated with before and after ADHD diagnosis in England.
- Trial name
- NCT05137704
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 2,236 people
- Sponsor
- Takeda
Attention Deficit Hyperactivity Disorder
A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators
The purpose of this study is to determine whether SPD465 is safe and effective in the treatment of ADHD in young adult drivers after a duration of 16 hours.
- Trial name
- NCT00458445
- Testing
- SPD465
- Where
- United States
- Sponsor
- Shire
Adult Attention-deficit/Hyperactivity Disorder
Integrated Diagnosis and Treatment of Adults With Attention-deficit/Hyperactivity Disorder
Non-interventional study to gain further information about the therapy progression in routine treatment of adults with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- IDEA (NCT01615679)
- Where
- Germany
- Volunteers
- 468 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
ADHD
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.
- Trial name
- NCT02168127
- Testing
- Drug: PRC-063, PRC-063
- Where
- 35 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder
Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
Attention Deficit Hyperactivity Disorder (ADHD) is a neurobiological disorder characterized by lifelong issues of inattention, distraction, organizational difficulties, forgetfulness, restlessness, talking out of turn, difficulty…
- Trial name
- ADD201 (NCT00983814)
- Testing
- Droxidopa+Carbidopa
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Chelsea Therapeutics